Su, MA
Chia-Chen Su, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20130194250 | METHODS FOR DRIVING ELECTRO-OPTIC DISPLAYS - A variety of methods for driving electro-optic displays so as to reduce visible artifacts are described. Such methods include (a) applying a first drive scheme to a non-zero minor proportion of the pixels of the display and a second drive scheme to the remaining pixels, the pixels using the first drive scheme being changed at each transition; (b) using two different drive schemes on different groups of pixels so that pixels in differing groups undergoing the same transition will not experience the same waveform; (c) applying either a balanced pulse pair or a top-off pulse to a pixel undergoing a white-to-white transition and lying adjacent a pixel undergoing a visible transition; (d) driving extra pixels where the boundary between a driven and undriven area would otherwise fall along a straight line; and (e) driving a display with both DC balanced and DC imbalanced drive schemes, maintaining an impulse bank value for the DC imbalance and modifying transitions to reduce the impulse bank value. | 08-01-2013 |
Christopher Z. Su, Westford, MA US
Patent application number | Description | Published |
---|---|---|
20140330775 | COMPARING MARKUP LANGUAGE FILES - Processing markup language files can include pre-processing an original file and a new file, wherein the original file and the new file are markup language files. Pre-processing includes removing tags from the original file and the new file resulting in a pure text version of the original file and a pure text version of the new file. Using a processor, the pure text version of the original file is compared with the pure text version of the new file to determine differences. The differences are specified in a comparison result. The comparison result is post-processed by applying formatting to the differences and tags from the new file. | 11-06-2014 |
20140330834 | COMPARING MARKUP LANGUAGE FILES - Processing markup language files can include pre-processing an original file and a new file, wherein the original file and the new file are markup language files. Pre-processing includes removing tags from the original file and the new file resulting in a pure text version of the original file and a pure text version of the new file. Using a processor, the pure text version of the original file is compared with the pure text version of the new file to determine differences. The differences are specified in a comparison result. The comparison result is post-processed by applying formatting to the differences and tags from the new file. | 11-06-2014 |
Dongling Su, Dorchester, MA US
Patent application number | Description | Published |
---|---|---|
20100130730 | PROTEIN FORMULATIONS FOR USE AT ELEVATED TEMPERATURES - Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature. | 05-27-2010 |
Dongling Su, Franklin, MA US
Patent application number | Description | Published |
---|---|---|
20090259023 | LIQUID BUFFERED GDF-5 FORMULATIONS - Improved formulations and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an acetate buffered solution of GDF-5 and other excipients wherein the solution has a pH of from about 4.2 to about 5.3, thereby providing for a biologically isotonic solution having improved stability of the GDF-5 protein during storage, handling, and use. | 10-15-2009 |
20090318343 | Protein Formulations for Use at Elevated Temperatures - Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature. | 12-24-2009 |
20110165242 | IN SITU GELLING DRUG DELIVERY SYSTEM - The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered. | 07-07-2011 |
20110237506 | PROTEIN STABILIZATION FORMULATIONS - The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants. | 09-29-2011 |
20120165257 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression. | 06-28-2012 |
20120165731 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression. | 06-28-2012 |
20120165787 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluraonic acid (“HA”), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans (“GAG”), such as chondroitin sulfate (“CS”), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (“GlcN”) | 06-28-2012 |
20130005681 | COMPOSITIONS AND METHODS FOR STABILIZED POLYSACCHARIDE FORMULATIONS - Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid (“HA”), in combination with at least one stabilizer. The composition can include a stabilizer that increases the stability and shelf-life of the HA. In another embodiment, the compositions and methods can also include an additional component, such as one or more glycosaminoglycans (“GAG”) or GAG precursors. Examples of GAGs or GAG precursors can include chondroitin sulfate (“CS”), dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and glucosamine (“GlcN”). | 01-03-2013 |
20130101656 | IN SITU GELLING DRUG DELIVERY SYSTEM - The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered. | 04-25-2013 |
20130172255 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression. | 07-04-2013 |
20130178827 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluraonic acid (“HA”), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans (“GAG”), such as chondroitin sulfate (“CS”), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (“GlcN”) | 07-11-2013 |
20130184209 | PROTEIN STABILIZATION FORMULATIONS - The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants. | 07-18-2013 |
20140088038 | COMPOSITIONS AND METHODS FOR STABILIZED POLYSACCHARIDE FORMULATIONS - Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid (“HA”), in combination with at least one stabilizer. The composition can include a stabilizer that increases the stability and shelf-life of the HA. In another embodiment, the compositions and methods can also include an additional component, such as one or more glycosaminoglycans (“GAG”) or GAG precursors. Examples of GAGs or GAG precursors can include chondroitin sulfate (“CS”), dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and glucosamine (“GlcN”). | 03-27-2014 |
20140336278 | In Situ Gelling Drug Delivery System - The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered. | 11-13-2014 |
20140343012 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluraonic acid (“HA”), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans (“GAG”), such as chondroitin sulfate (“CS”), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (“GlcN”) | 11-20-2014 |
20140363482 | Bioerodible Sustained Release Drug Delivery Systems - The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery. | 12-11-2014 |
20150079145 | PROTEIN STABILIZATION FORMULATIONS - The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants. | 03-19-2015 |
20150190469 | Methods for Forming Compositions for Treating Joints Comprising Bone Morphogenetic Protein and Hyaluronic Acid - Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression. | 07-09-2015 |
Fang Su, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20140256795 | CO-ACTIVATION OF MTOR AND STAT3 PATHWAYS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION - Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods. | 09-11-2014 |
Guolong Su, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20160043756 | Mixer Sequence Design For N-Path Filters - A bandpass filter includes a plurality of parallel paths, each receiving the input signal to the bandpass filter. Each path includes a first mixer, a low-pass filter, and a second mixer. The first mixer in each path is coupled to receive the input signal and mixes the input signal with a periodic mixer sequence having a period that is divided into a plurality of time slots. The mixer value is constant during each time slot. The low-pass filter in each path is operable to filter an output of the associated first mixer. The second mixer in each path is coupled to receive an output of the associated low-pass filter and mixes said filter output with a periodic mixer sequence having a period that is divided into a plurality of time slots, wherein again the mixer value is constant during each time slot. A summer sums the outputs of the second mixers of each of the paths to generate an output of the bandpass filter. | 02-11-2016 |
Hao Su, Worcester, MA US
Patent application number | Description | Published |
---|---|---|
20120265051 | APPARATUS AND METHODS FOR MRI-COMPATIBLE HAPTIC INTERFACE - In one embodiment, the system of these teachings includes a master robot/haptic device providing haptic feedback to and receiving position commands from an operator, a robot controller receiving position information and providing force information to the master robot/haptic device, a navigation component receiving images from an MRI scanner, the navigation component providing trajectory planning information to the robot controller, a slave robot driving a needle, the slave robot receiving control information from the robot MRI controller, and a fiberoptic sensor operatively connected to the slave robot; the fiberoptic sensor providing data to the robot controller; the data being utilized by the robot controller to provide force information to the master robot/haptic device. In one instance, the present teachings include a fiberoptic force sensor and an apparatus for integrating the fiberoptic sensor into a teleoperated MRI-compatible surgical system. Methods for use are disclosed. | 10-18-2012 |
20130078600 | SYSTEM AND METHOD OF PERVASIVE DEVELOPMENTAL DISORDER INTERVENTIONS - Methods and systems for observing/analyzing, interactive behavior are presented. In one instance, the method for observing/analyzing interactive behavior includes interacting, using a robot, with a subject and obtaining data from interaction between the subject and the robot, the data from the data acquisition components, the data being used for diagnosis and/or charting progress. In one instance, the robot includes data acquisition components, interaction inducing components (such as, but not limited to, movable eyelids, movable appendages, sound generating components), a control component operatively connected to the interaction inducing components and a processing component operatively connected to the control component and the data acquisition components, the processing component being configured to obtain data from the data acquisition components, the data being used for diagnosis and/or charting progress. In one instance, the robot is integrated with a computer-aided system for diagnosis, monitoring, and therapy. | 03-28-2013 |
20140107569 | SYSTEM AND METHOD FOR UNDERACTUATED CONTROL OF INSERTION PATH FOR ASYMMETRIC TIP NEEDLES - A needle steering system and apparatus provides active, semi-autonomous control of needle insertion paths while still enabling a clinician ultimate control over needle insertion. The present teaching describes a method and system for controlling needle path as the needle is inserted by precisely controlling the rotation of the needle as it continuously rotates during insertion. This enables underactuated 2 degree-of-freedom (DOF) control of the direction and the curvature of the needle from a single rotary actuator. Control of the rotary motion is therefore decoupled from the needle insertion. The rotary motion controls steering effort and direction, while the insertion controls needle depth or insertion speed. In one implementation, the proposed method does not require constant velocity insertion, interleaved insertion and rotation, or known insertion position or speed. The insertion may be provided by a robot or other automated method, may be a manual insertion, or may be a teleoperated insertion | 04-17-2014 |
Junwei Su, Lowell, MA US
Patent application number | Description | Published |
---|---|---|
20160131615 | HIGH PERFORMANCE QUARTZ CRYSTAL MICROBALANCE ENHANCED BY MICROSTRUCTURES FOR BIOLOGICAL APPLICATIONS - Quartz crystal microbalance resonators are described, as are methods of making them using micron sized pillar array of polymethyl methacrylate fabricated on a QCM surface using a nanoimprint lithography process. Their use in any applications, including for example gas and liquid sensors and biosensors as well as other measurement applications, is also discussed. | 05-12-2016 |
Li Su, Somerville, MA US
Patent application number | Description | Published |
---|---|---|
20110086796 | METHODS FOR PREDICTING THE DEVELOPMENT AND RESOLUTION OF ACUTE RESPIRATORY DISTRESS SYNDROME - The subject invention features methods for predicting whether a subject at risk of developing Acute Respiratory Distress Syndrome (ARDS) will develop ARDS by determining the amount of elafin present in a subject sample, or by determining the ration of elafin:neutrophil elastase in a subject sample. The invention also features methods for monitoring the efficacy of a treatment regimen for ARDS as well as methods of treatment for ARDS. The invention also features methods to determine a subject's predisposition for developing ARDS by determining whether certain genomic polymorphisms are present in the subject's DNA. | 04-14-2011 |
Liang Su, Somerville, MA US
Patent application number | Description | Published |
---|---|---|
20150236543 | MATERIALS FOR USE WITH AQUEOUS REDOX FLOW BATTERIES AND RELATED METHODS AND SYSYTEMS - Described herein are redox flow batteries comprising a first aqueous electrolyte comprising a first type of redox active material and a second aqueous electrolyte comprising a second type of redox active material. The first type of redox active material may comprise one or more types of quinoxalines, or salts thereof. Methods for storing and releasing energy utilizing the described redox flow batteries are also provided. | 08-20-2015 |
Liansheng Su, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20120028969 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF - The present invention provides compounds of formula (I); | 02-02-2012 |
Liguo Su, Billerica, MA US
Patent application number | Description | Published |
---|---|---|
20150042206 | TRANSDUCER SYSTEMS - Transducer systems with reduced acoustic noise coupling are disclosed herein. In some embodiments, a transducer system includes pressure balancing features to prevent a floating portion of the transducer system from contacting a fixed portion of the transducer system, or to reduce the degree to which the floating portion is urged into contact with the fixed portion by process pressure or atmospheric pressure. In some embodiments, a transducer system includes one or more acoustic dampening elements, interruption grooves, annular projections, or dampening washers to reduce acoustic noise coupling between various components of the transducer system or between the transducer system and a flowcell in which the transducer system is mounted. | 02-12-2015 |
Lihe Su, Reading, MA US
Patent application number | Description | Published |
---|---|---|
20090220998 | Platelet Aggregation Assays - The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto. | 09-03-2009 |
20100104573 | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF - This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions. | 04-29-2010 |
20130045219 | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF - This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions. | 02-21-2013 |
20130189713 | PLATELET AGGREGATION ASSAYS - The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto. | 07-25-2013 |
20140302016 | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF - This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions. | 10-09-2014 |
20140369940 | Anti-Alpha Synuclein Binding Molecules - Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively. | 12-18-2014 |
Mei Su, Waltham, MA US
Patent application number | Description | Published |
---|---|---|
20080287475 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer - This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer. | 11-20-2008 |
20090054396 | SUBSTITUTED THIOPHENES AND USES THEREOF - This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer. | 02-26-2009 |
20100160325 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER - This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer. | 06-24-2010 |
20100324040 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer. | 12-23-2010 |
20110183954 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS - The present invention relates to compounds of Formula (I): (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer. | 07-28-2011 |
20110201628 | HETEROCYCLIC JAK KINASE INHIBITORS - The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer. | 08-18-2011 |
20120071480 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER - This invention relates to novel compounds having the formula (I): | 03-22-2012 |
20140155394 | Chemical Compounds - 759 - The present invention relates to compounds of Formula (I): | 06-05-2014 |
Mei Su, Marlborough, MA US
Patent application number | Description | Published |
---|---|---|
20080207616 | Quinoxalines as B Baf Inhhibitors - The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man. | 08-28-2008 |
Michael Su, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20090203702 | INHIBITORS OF p38 - The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders. | 08-13-2009 |
20110178069 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME - The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds. | 07-21-2011 |
20110281878 | INHIBITORS OF p38 - The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders. | 11-17-2011 |
20120165319 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME - The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds. | 06-28-2012 |
Michael S. Su, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20090186394 | Crystallizable JNK complexes - The present invention relates to a data storage medium encoded with the corresponding structure coordinates of molecules and molecular complexes which comprise the active site binding pockets of JNK3. A computer comprising such data storage material is capable of displaying such molecules and molecular complexes, or their structural homologues, as a graphical three-dimensional representation on a computer screen. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen and design compounds, including inhibitory compounds, that bind to JNK3 or homologues thereof. This invention also relates to molecules and molecular complexes which comprise the active site binding pockets of JNK3 or close structural homologues of the active site binding pockets. | 07-23-2009 |
Ming Su, Chestnut Hill, MA US
Patent application number | Description | Published |
---|---|---|
20150092811 | Nanoparticles-Based Taggant Systems and Methods - Coding systems may include an object and a taggant linked to the object, the taggant comprising one or more types of phase change nanoparticles, each type of phase change nanoparticles having a phase change temperature different from a phase change temperature of other types of phase change nanoparticles, wherein, when the taggant is thermally scanned, different phase change temperatures result in one or more predefined melting peaks forming a code that represents information particular to the object. | 04-02-2015 |
Mingjuan Su, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20140124762 | ORGANIC CONDUCTIVE MATERIALS AND DEVICES - Embodiments described herein relate to compositions including iptycene-based structures and extended iptycene structures. In some embodiments, the compositions may be useful in organic light-emitting diodes (OLEDs), organic photovoltaics, and other devices. | 05-08-2014 |
Qibin Su, Waltham, MA US
Patent application number | Description | Published |
---|---|---|
20090105324 | IMIDAZOLE DERIVATIVES FOR USE AS EDG-1 ANTAGONISTS - The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man. | 04-23-2009 |
20090111860 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS - The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant vascularization or inflammatory component such as in tumor-related diseases. The present invention also relates to compounds that inhibit a5bl, and also that exhibit appropriate selectivity profile(s) against other integrins. | 04-30-2009 |
20100029643 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY - The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man. | 02-04-2010 |
20100197749 | CHEMICAL COMPOUNDS - The invention relates to chemical compounds of formula (I) and (II): | 08-05-2010 |
20110201628 | HETEROCYCLIC JAK KINASE INHIBITORS - The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer. | 08-18-2011 |
20110218182 | CHEMICAL COMPOUNDS 251 - The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer. | 09-08-2011 |
20150051185 | Chemical Compounds 251 - The invention relates to chemical compounds of formula I, | 02-19-2015 |
Shinsan Su, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20120041070 | METHODS OF TREATING CANCER HAVING AN ABERRANT EGFR OR KRAS GENOTYPE - The invention relates to the treating cancer having an aberrant EGFR or KRAS genotype, with an AMPK activator, as well as related methods, compounds and compositions. | 02-16-2012 |
20120121515 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods of treating and evaluating subjects having neoactive mutants are described herein. | 05-17-2012 |
Shin-San M. Su, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20140148444 | METHODS OF USING PYRUVATE KINASE ACTIVATORS - Described herein are compounds that activate pyruvate kinase, for use in a method for increasing lifetime of the red blood cells, for regulating 2,3-diphosphoglycerate levels in blood and for treating sickle cell anemia. | 05-29-2014 |
20140155374 | METHODS OF USING PYRUVATE KINASE ACTIVATORS - Described herein are methods for using compounds that activate pyruvate kinase. | 06-05-2014 |
20140179694 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA - Described herein are methods for using compounds that activate pyruvate kinase. | 06-26-2014 |
20140194402 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY - Described herein are methods for using compounds that activate pyruvate kinase. | 07-10-2014 |
Shin-San Michael Su, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20150240286 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2). | 08-27-2015 |
20160106742 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY - Described herein are methods for using compounds that activate pyruvate kinase. | 04-21-2016 |
Shin-San Michael Su, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20130183281 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2). | 07-18-2013 |
20130197106 | METHODS OF IDENTIFYING A CANDIDATE COMPOUND - The invention relates to methods identifying compounds for the treatment of cell proliferation-related disorders, e.g., proliferative disorders such as cancer. | 08-01-2013 |
20130288284 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2). | 10-31-2013 |
20130316385 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods and compositions for treating and evaluating subjects having a neoactive mutation at residue 97 of IDH1 or 137 of IDH2. | 11-28-2013 |
20140155408 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY - Described herein are methods for using compounds that activate pyruvate kinase. | 06-05-2014 |
20140187435 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods of treating and evaluating subjects having neoactive mutants are described herein. | 07-03-2014 |
Stephen Su, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20140294834 | TANDEM FC BISPECIFIC ANTIBODIES - Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific. | 10-02-2014 |
20140302035 | ANTI-C-MET Tandem Fc Bispecific Antibodies - Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific. | 10-09-2014 |
Tianxiang Su, Somerville, MA US
Patent application number | Description | Published |
---|---|---|
20150159447 | METHOD AND SYSTEM FOR EXTENDING REACH IN DEVIATED WELLBORES USING SELECTED INJECTION SPEED - A method for extending reach of a coiled tubing string in a deviated wellbore includes vibrating the tubing string while the tubing string is injected into the wellbore at a first injection speed, finding the peak speed of lateral vibration of the tubing string, determining a second injection speed as a function of the obtained peak speed of lateral vibration, and adjusting the injection speed of the vibrating tubing string from the first injection speed to the determined second injection speed based on said function. A non-transitory computer-readable storage medium to execute the foregoing method is provided, along with a system for extending reach of a coiled tubing string in a deviated wellbore. | 06-11-2015 |
Wenbo Su, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20150222744 | UNIFIED CALL LOGS - A user device may identify a received a signal indicating an incoming call; determine that another user device has answered the call; generate call log information that indicates that the other user device has answered the call; and store or output the generated call log information. Additionally, or alternatively, a set of user devices may receive a ring signal indicating an incoming call; a particular user device, in the set of user devices, may answer the call; and another user device, in the set of user devices, may store a unified call log. The unified call log may indicate that the particular user device answered the call, and may further indicate that the other user device did not miss the call. | 08-06-2015 |
20150278504 | USER AUTHENTICATION BASED ON ESTABLISHED NETWORK ACTIVITY - A device may determine that a user device should be authenticated; and determine a confidence measurement based on an established activity pattern of the user device. The confidence measurement may relate to a likelihood that an authorized user of the user device is in possession of the user device. The device may authenticate the user device based on the confidence measurement. | 10-01-2015 |
Yang Su, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20150343402 | INTERACTION CHAMBERS WITH REDUCED CAVITATION - Apparatuses and methods that reduce cavitation in interaction chambers are described herein. In an embodiment, an interaction chamber for a fluid processor or fluid homogenizer includes an inlet chamber having an inlet hole and a bottom end, an outlet chamber having an outlet hole and a top end, a microchannel placing the inlet hole in fluid communication with the outlet hole, wherein an entrance to the microchannel from the inlet chamber is offset a distance from the bottom end, and at least one of: (i) a tapered fillet located on a side wall of the microchannel at the microchannel entrance; (ii) a side wall of the microchannel converging inwardly from the inlet chamber to the outlet chamber; (iii) a top wall and/or bottom wall of the microchannel angled from the inlet chamber to the outlet chamber; and (iv) a top fillet that extends around a diameter of inlet chamber. | 12-03-2015 |
Yi Su, Bedford, MA US
Patent application number | Description | Published |
---|---|---|
20160080198 | WIRELESS MESH NETWORK FIRMWARE UPGRADE SYSTEM AND METHOD - A wireless mesh access point receives a first notification of firmware download availability. In response to the first notification, the wireless mesh access point downloads a firmware file from a peer from which the first notification was received. The wireless mesh access point loads the downloaded firmware file into a firmware memory associated with operation of a processor. The wireless mesh access point then transmits a second notification of firmware download availability to one or more other peers. | 03-17-2016 |
Zhuang Su, Andover, MA US
Patent application number | Description | Published |
---|---|---|
20130210704 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF - The present invention relates to a compound of the Formula (I)): | 08-15-2013 |
20130303438 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION - The present invention relates to a compound of the formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same. | 11-14-2013 |
20140005100 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | 01-02-2014 |
20150111815 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS - The present invention relates to a compound of formula (I): | 04-23-2015 |
20160039879 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF - The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss. | 02-11-2016 |
20160052972 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION - The present invention relates to a compound of the formula (I): | 02-25-2016 |